1. Versatis Summary of Product Characteristics, Jun.2013.

2. Rehm et al. Post-Herpetic Neuralgia: 5% lidocaine medicated plaster, pregabalin, or a combination of both? A randomized, open, clinical effectiveness study. Curr Med Res Opin 2010;26(7):1607-19.

3. Baron R et al. 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. Curr Med Res Opin 2009;25:1663 -76.

4. Sabatowski R et al. Safety and Efficacy Outcomes of Long-term Treatment up to 4 Years with 5% Lidocaine Medicated Plaster in Patients with Post-Herpetic Neuralgia.Curr Med Res Opin 2012;28:1-10.

5. Boesl, I. Koenig, S. MORE THAN 18 MILLION PATIENTS USED 5% LIDOCAINE MEDICATED PLASTER (5%LMP): AN UPDATE ON ITS SAFETY PROFILE. In: International Pain in Europe Congress (EFIC); Oct 9 - 12, 2013; Florence, Italy. 2013; Poster 1003

6. Attal et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J of Neurology 2010; 17:1113-23.

7. Davies PS, Galer BS. Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia. Drugs 2004;64:937–47.

8. Dalpiaz AS, Lordon SP, Lipman AG. Topical lidocaine patch therapy for myofascial pain. J Pain Palliat Care Pharmacother 2004;18:15–34.

9. Argoff CE, Katz N, Backonja M. Treatment of Postherpetic Neuralgia: A review of therapeutic options. J Pain Symptom Manag 2004; 28 (4): 396-411.

10. Vadalouca A et al. Therapeutic management of chronic neuropathic pain: an examination of pharmacologic treatment. Ann N Y Acad Sci 2006;1088:164–86.

11. Hanna M et al. Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. Eur J Pain 2008;12:804–13.

12. Oster G et al. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain 2005;6:356–63.

13. van Seventer R et al. A cross-sectional survey of health state impairment and treatment patterns in patients with postherpetic neuralgia. Age Ageing 2006;35:132–7.

14. Gore M et al. Selecting an appropriate medication for treating neuropathic pain in patients with diabetes: a study using the U.K. and Germany Mediplus databases. Pain Pract 2008;8:253–62.

15. Attal N et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006;13:1153–69.

16. Dworkin RH et al. Diagnosis and Assessment of Pain Associated With Herpes Zoster and Postherpetic Neuralgia. J Pain 2008;9(1):S37-S44.

17. Moulin DE et al. Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag 2007;12:13–21.

18. Gilron I et al. Neuropathic pain: a practical guide for the clinician. CMAJ 2006;175:265–75.

19. O’Connor AB, Dworkin RH: Treatment of Neuropathic Pain: An Overview of Recent Guidelines. The American Journal of Medicine. 2009 Oct; 122(10 Suppl): S22-32.

20. Garnock-Jones KP, Keating GM, Lidocaine 5 % Medicated Plaster. Drugs 2009: 69 (15); 2149-2165.

21. Dworkin RH, Portenoy RK. Pain and its persistence in herpes zoster. Pain 1996; 67: 241 – 51.

+ compared to Pregabalin